# US 11,299,537 B2 · Methods for treatment of motor neuron diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,537 B2
- Document ID: US11299537B2
- Status: Granted
- Kind: B2
- Application number: 16/060,301
- Filed: 2016-12-06
- Published: 2019-01-03
- Granted: 2022-04-12
- Earliest claimed: 2015-12-10
- Assignees: FibroGen, Inc.
- Applicants: FibroGen, Inc.
- Inventors: Enrique Brandan; David Gonzalez
- Web page: https://patentgrep.com/patent/US11299537B2

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/475: Growth factors; Growth regulators
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.

## Claims

### Claim 1

A method of ameliorating weight loss of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby ameliorating the subject with ALS loss of weight.

### Claim 2

A method of reducing muscle atrophy of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing muscle atrophy of the subject with ALS.

### Claim 3

A method of preserving muscle strength of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby preserving muscle strength of the subject with ALS.

### Claim 4

A method of reducing nerve demyelination of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing nerve demyelination of the subject with ALS.

### Claim 5

A method of reducing disease progression of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing disease progression of the subject with ALS.

### Claim 6

A method of reducing loss of movement of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing loss of movement of the subject with ALS.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the effective amount of the anti-CTGF antibody is at least 10 mg/kg.

### Claim 8 (depends on 7)

The method of claim 7, further comprising the administration of riluzole.